MentiNova, Inc is dedicated to the clinical development
of therapeutics to benefit patients afflicted with Parkinson’s disease
Parkinson’s disease is a chronic, progressive, neurodegenerative disorder affecting one million people in the United States and seven million worldwide. Disease symptoms can be ameliorated by the drug L-DOPA; however, its chronic use eventually leads to the majority of patients developing involuntary movements known as L-Dopa Induced Dyskinesia (LID), which itself can be disabling. Currently, the medical management of these complications is a major unmet need for this patient population.
MentiNova’s primary strategy is to use a drug that is currently clinically approved for another indication and repurpose it for the treatment of L-Dopa Induced Dyskinesia in patients with Parkinson’s disease. This path can provide a critically needed medication in a rapid timeframe. MentiNova is aggressively pursuing development with comprehensive scientific, clinical and business considerations to expeditiously provide benefit to patients.
MentiNova receives seed funding.
Foundation Venture Capital Group makes investment to advance MentiNova's program to treat L-Dopa induced dyskinesia.